Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial
Objectives : Obesity and hypertension are associated with an adverse metabolic profile and systemic low- grade inflammation . Metformin reduces weight and inflammation in patients with diabetes , but it is unclear whether it has beneficial effects in patients without diabetes . The objective was to explore whether metformin-based treatment could benefit obesity-related hypertension without diabetes . Methods : A r and omized , double-blind , placebo-controlled factorial trial was conducted in 360 obese hypertensive patients without diabetes in Chongqing , China . After a 1–2-week run-in period , patients were r and omly assigned to metformin ( 500 mg once per day ) or placebo , as well as to an antihypertensive medication .  Change in blood pressure , obesity measurements and metabolic profile were assessed at 24 weeks . Results : The 180 participants r and omized to metformin and 180 r and omized to placebo were similar at baseline . At 24 weeks , metformin compared with placebo did not have significant effects on blood pressure , blood glucose , high-density or low-density lipoprotein cholesterol , but it did reduce total serum cholesterol ( 0.27mmol/l , P = 0.038 ) . Metformin also significantly reduced weight ( −0.7 kg , P = 0.006 ) , BMI ( −0.2 kg/m2 , P = 0.024 ) , waist circumference ( −0.9 cm , P = 0.008 ) , and both subcutaneous ( −6.1 cm2 , P = 0.043 ) and visceral adiposity ( −5.4 cm2 , P = 0.028 ) as measured by computed tomography , and lowered serum high-sensitivity C-reactive protein levels ( −0.6 mg/dl , P < 0.001 ) . There was no significant difference in adverse events ( P = 0.785 ) . Conclusions : Metformin has no effect on blood pressure and blood glucose levels , but it does reduce total cholesterol , abdominal obesity and C-reactive protein levels in obese hypertensive patients without diabetes
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .